Review: Myeloid-derived suppressor cells (MDSCs) – Will it become a therapeutic target for Non- Hodgkin Lymphoma?
- July 6, 2021
- Posted by: RSIS
- Categories: Health Sciences, IJRIAS
International Journal of Research and Innovation in Applied Science (IJRIAS) | Volume VI, Issue V, May 2021|ISSN 2454-6194
Darshana Kottahachchi, Sachini Gallage, Chamila Nandasena
Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, General Sir John Kotelawala Defence University, Sri Lanka
Abstract: Non-Hodgkin’s lymphoma (NHL) is a varied set of lymphoproliferative disorders initiatingfrom B, T, or natural killer (NK) lymphocytes. Common treatments of NHL include chemotherapy regimens, radiotherapy, rituximab administration, transfusion of blood products and Peripheral blood stem cell transplantation. Recently, several targeted therapies have been approved or are in the later phase of clinical trials and molecular targeted therapy is considered as a key aspect of NHL. Successful treatment of lymphoma may result from the induction of specific antitumor immunity. Myeloid-derived suppressor cells (MDSC) are being investigated as a possible target in solid tumors and most of blood cancers to improve the effects of commonly used undergoing treatment. The anti-tumor immune response of a diseased person is inhibited by MDSC expansion, which restricts, cytokine secretion, T cell proliferation and the activation of regulatory T cells. In order to identify immunological therapeutic targets, it is critical to identify tumor-promoting factors. Since this environment is focus to low selective pressure for mutations, targeting the Tumor Microenvironment (TME) is a promising therapeutic option for Non-Hodgkin lymphoma. The features, distribution, roles, cellular reactions, and aiming MDSCs in Non-Hodgkin lymphoma are discussed in this review.
Key Words; Non-Hodgkin lymphoma, Myeloid-derived suppressor cells, Target therapy, TEM
I. INTRODUCTION
A. What is Non-Hodgkin Lymphoma
The word Non- Hodgkin’s Lymphoma (NHL) addresses a number of lymphoproliferative diseasescaused by B, T, or natural killer (NK) lymphocytes (Zelenetz et al., 2011)andmore NHLs are originated from B lymphocytes (Bowzyk Al-Naeebet al.,2018). NHL is divided into more than 40 subtypes, ranging from low-grade indolent cancers to high-grade chronic cancers (Warawita et al., 2014, Bowzyk Al-Naeebet al.,2018).They are composed primarily of lymphocytes in different stages of development. As a result, the characteristics of each lymphoma subtype are determined by the cell that gave rise to them(Shankland et al., 2012).
